This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised
by Zacks Equity Research
Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.
Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer
by Zacks Equity Research
Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.
Pfizer (PFE) Beats on Q2 Earnings, to Merge Upjohn With Mylan
by Zacks Equity Research
Pfizer (PFE) beats estimates for second-quarter earnings but misses on sales. The company also lowers 2019 earnings and sales guidance.
Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment
by Kinjel Shah
AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.
Glaxo (GSK) Beats on Q2 Earnings, Shingrix Sales Strong
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the second quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
What to Expect from Sanofi's (SNY) Q2 Earnings
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
Glaxo (GSK) Beats Earnings & Revenue Estimates in Q2
by Indrajit Bandyopadhyay
Glaxo beats both earnings and sales estimates in the second quarter of 2019.
Should You Buy Glaxo (GSK) Ahead of Earnings?
by Zacks Equity Research
Glaxo (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Allergan (AGN) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.
Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
by Zacks Equity Research
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
Gilead-Galapagos Ink $5.1B Deal for Additional Compounds
by Zacks Equity Research
Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
by Kinjel Shah
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill
by Zacks Equity Research
Glaxo's (GSK) phase III study, evaluating the efficacy of switching to Dovato from a three-drug TAF based regimen, meets the primary endpoint.
Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status
by Zacks Equity Research
Glaxo's (GSK) long-acting, injectable two-drug regimen gets FDA's priority review designation. The company begins study to identify approaches to implementing once-monthly injectable HIV treatment in the real world.
Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs
by Kinjel Shah
Pfizer (PFE) provides several regulatory/pipeline updates. CHMP gives nod to several drugs.
Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III
by Zacks Equity Research
Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.
Roche's Flu Medicine Xofluza Meets Goal in Study on Kids
by Zacks Equity Research
Roche's (RHHBY) new flu medicine, Xofluza is well tolerated in a study in children aged between one to 12 years. It is also comparable to Roche's older flu medicine, Tamiflu,
AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label
by Zacks Equity Research
AstraZeneca (AZN) gets positive CHMP opinion for self-administration option for Fasenra and the Fasenra pen and to include outcomes data on Forxiga???s label.
Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger
by Kinjel Shah
AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
by Zacks Equity Research
Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
by Zacks Equity Research
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
by Zacks Equity Research
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.